Episode 65 - Audience proposed question: Guidance for potential treatments of CSU

Professor Martin Metz joins Professor Marcus Maurer to answer an audience proposed question focusing on what will guide physicians in the recommendations for individual patients to identify the most beneficial treatment option to treat chronic spontaneous and inducible urticaria. Both experts delve into the current treatment options available, and exciting treatments that are currently in clinical trials. Do you have suggestions for future episodes? Please provide feedback and offer your suggestions for future topics and expert selection here. Utilise the following external links to access additional resources relating to the topics discussed in this episode: Dupilumab in CSU, Remibrutinib in CSU, Bruton's tyrosine kinase inhibition—An emerging therapeutic strategy in immune-mediated dermatological conditions, An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria, Barzolvolimab in mast cell depletion, Chronic spontaneous urticaria: Focus on pathophysiology to unlock treatment advances, Chronic urticaria and the pathogenic role of mast cells and Urticaria (an overview). Access additional resources by signing up to Medthority and to be notified for future 'All Things Urticaria' podcast episodes!  For more information about the UCARE/ACARE network and its activities, please visit: UCARE Website, UCARE LevelUp Program, ACARE Website, UCARE 4U Website, UDAY Website, CRUSE Control App and CURE Registry.

There are no comments yet.

Please log in to write the first comment.